ZALTRAP 25 mg/ml concentrate
ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Home | ziv-aflibercept solution
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ZALTRAP 25 mg/ml concentrate
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer.
Zaltrap is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) for whom treatment based on another medicine, oxaliplatin, has not worked or the cancer got worse. Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid. The medicine contains the active substance aflibercept. The European Commission granted a marketing authorisation valid throughout the European Union for Zaltrap on 1 February 2013.
Aflibercept (Eylea) is indicated for the treatment of people with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity. Aflibercept (Zaltrap), in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of people with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. It is used for the treatment of wet macular degeneration and is administered as an intravitreal injection, that is, into the eye. For cancer treatment, it is given intravenously in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI). In August 2014, aflibercept (Eylea) was approved for the treatment of people with visual impairment due to diabetic macular edema, according to the updated summary of product characteristics. In May 2019, the US FDA expanded the indication for aflibercept to include all stages of diabetic retinopathy. In February 2023, the US FDA approved aflibercept (Eylea) as a treatment for retinopathy of prematurity.
Drug (Brand / Generic): ZALTRAP / Ziv-Aflibercept
Current Indications: Colorectal Neoplasms
Marketed by:: Sanofi Winthrop Industrie
Approval Date: 01/02/2013
Available as (Form & Strength): 100 mg/4 mL (25 mg/mL) and 200 mg/8 mL (25 mg/mL).
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ ZALTRAP (Aflibercept) Injection ”. Confirmation of the order for ZALTRAP (Aflibercept) Injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – ZALTRAP
For personal use, get access to an imported medicines (unapproved drug in India) for Colorectal Cancer. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Karnataka, Bangalore, Bhopal, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Dispur, Guwahati, Dehradun, Lucknow, Surat, Nagpur, New Delhi, Pondichery, Pune, Itanagar, Bathinda, Thirunananthapuram, Visakhapatnam, Chandigarh, Faridabad, Gurgaon, Agartala, Shillong, Goa, Wardha, Shimla, Dharamshala, Aizawl, Noida, Ghaziabad, Punjab.
ZALTRAP Sourcing & Delivery
Alleviare India specializes in sourcing and supplying ZALTRAP, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of ZALTRAP in India.
How much does ZALTRAP cost in the India?
Kindly reach out to us for ZALTRAP (Aflibercept) Injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import ZALTRAP to India?
To import Aflibercept ZALTRAP, patients or government hospitals can place an order on behalf of the patients.
The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is ZALTRAP available in India?
ZALTRAP Aflibercept is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of ZALTRAP (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for ZALTRAP availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is Aflibercept available in India?
U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI), for patients with metastatic colorectal cancer (mCRC).
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ZALTRAP (Aflibercept) Injection . The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to ZALTRAP (Aflibercept) Injection , they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
